Literature DB >> 21145863

Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice.

Susanna M van Aalten1, Joanne Verheij, Turkan Terkivatan, Roy S Dwarkasing, Robert A de Man, Jan N M Ijzermans.   

Abstract

BACKGROUND & AIMS: A molecular and pathological classification system for hepatocellular adenomas (HCA) was recently introduced and four major subgroups were identified. We aimed to validate this adenoma classification system and to determine the clinical relevance of the subtypes for surgical management.
METHODS: Paraffin fixed liver tissue slides and resection specimens of patients radiologically diagnosed as HCA were retrieved from the department of pathology. Immunostainings included liver-fatty acid binding protein (L-FABP), serum amyloid A (SAA), C-reactive protein (CRP), glutamine synthetase (GS) and β-catenin.
RESULTS: From 2000 to 2010, 58 cases (71 lesions) were surgically resected. Fourteen lesions were diagnosed as focal nodular hyperplasia with a characteristic map-like staining pattern of GS. Inflammatory HCA expressing CRP and SAA was documented in 36 of 57 adenomas (63%). Three of these inflammatory adenomas were also β-catenin positive as well as GS positive and only one was CRP and SAA and GS positive. We identified eleven L-FABP-negative HCA (19%) and four β-catenin positive HCA (7%), without expression of CRP and SAA and with normal L-FABP staining, one of which was also GS positive. Six HCA were unclassifiable (11%). In three patients multiple adenomas of different subtypes were found.
CONCLUSIONS: Morphology and additional immunohistochemical markers can discriminate between different types of HCA in>90% of cases and this classification, including the identification of β-catenin positive adenomas may have important implications in the decision for surveillance or treatment. Interpretation of nuclear staining for β-catenin can be difficult due to uneven staining distribution or focal nuclear staining and additional molecular biology may be required.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145863     DOI: 10.1016/j.jhep.2010.10.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  29 in total

Review 1.  Focal nodular hyperplasia and hepatic adenoma: current diagnosis and management.

Authors:  Agustin Cristiano; Agustin Dietrich; Juan Carlos Spina; Victoria Ardiles; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2013-06-27

2.  Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.

Authors:  Christian Grieser; Ingo G Steffen; Incken-Birthe Kramme; Hendrik Bläker; Ergin Kilic; Carmen Maria Perez Fernandez; Daniel Seehofer; Eckart Schott; Bernd Hamm; Timm Denecke
Journal:  Eur Radiol       Date:  2014-06       Impact factor: 5.315

Review 3.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

Review 4.  Malignant transformation of hepatocellular adenoma.

Authors:  Christine Sempoux; Charles Balabaud; Paulette Bioulac-Sage
Journal:  Hepat Oncol       Date:  2014-12-11

Review 5.  Genotype-phenotype correlations in hepatocellular adenoma: an update of MRI findings.

Authors:  Maarten G Thomeer; Mirelle E E Bröker; Quido de Lussanet; Katharina Biermann; Roy S Dwarkasing; Rob de Man; Jan N Ijzermans; Marianne de Vries
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

Review 6.  Management of hepatic adenomatosis.

Authors:  Manish Thapar; Oleg Grapp; Constantine Fisher
Journal:  Curr Gastroenterol Rep       Date:  2015-03

7.  Pigmented hepatocellular adenomas have a high risk of atypia and malignancy.

Authors:  Taofic Mounajjed; Saba Yasir; Patrice A Aleff; Michael S Torbenson
Journal:  Mod Pathol       Date:  2015-07-24       Impact factor: 7.842

8.  Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.

Authors:  Edouard Reizine; Giuliana Amaddeo; Frederic Pigneur; Laurence Baranes; François Legou; Sebastien Mulé; Benhalima Zegai; Vincent Roche; Alexis Laurent; Alain Rahmouni; Julien Calderaro; Alain Luciani
Journal:  Eur Radiol       Date:  2018-05-02       Impact factor: 5.315

9.  Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver?

Authors:  Mariko Kumagawa; Naoki Matsumoto; Yukinobu Watanabe; Midori Hirayama; Takao Miura; Hiroshi Nakagawara; Masahiro Ogawa; Shunichi Matsuoka; Mitsuhiko Moriyama; Tadatoshi Takayama; Masahiko Sugitani
Journal:  World J Hepatol       Date:  2016-09-18

10.  Overview of hepatocellular adenoma in Japan.

Authors:  Motoko Sasaki; Yasuni Nakanuma
Journal:  Int J Hepatol       Date:  2012-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.